| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/01/2007 | CA2616035A1 Compositions and methods for wood preservation |
| 02/01/2007 | CA2616028A1 Synthesis of scabronines and analogues thereof |
| 02/01/2007 | CA2615946A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors |
| 02/01/2007 | CA2615774A1 Large substituent, non-phenolic opioids |
| 02/01/2007 | CA2615718A1 Aniline sulfonamide derivatives and their uses |
| 02/01/2007 | CA2615710A1 Sensitization of immune system against haptenized melanoma antigens |
| 02/01/2007 | CA2615700A1 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
| 02/01/2007 | CA2615678A1 Isotopically substituted pantoprazole |
| 02/01/2007 | CA2615670A1 Isotopically substituted proton pump inhibitors |
| 02/01/2007 | CA2615663A1 Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors |
| 02/01/2007 | CA2615581A1 Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase |
| 02/01/2007 | CA2615577A1 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
| 02/01/2007 | CA2615474A1 Method for treating nervous system disorders and conditions |
| 02/01/2007 | CA2615063A1 High drug load formulations and dosage forms |
| 02/01/2007 | CA2614919A1 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders |
| 02/01/2007 | CA2610749A1 Pharmaceutical composition comprising 2,3-dihydro-6-nitroimidazo [2,1-b]oxazole derivatives |
| 02/01/2007 | CA2608733A1 Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| 02/01/2007 | CA2606933A1 Steroid kit and foamable composition and uses thereof |
| 02/01/2007 | CA2582311A1 Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases with ctc-96 |
| 02/01/2007 | CA2581831A1 Pharmaceutical compositions comprising levetiracetam and process for their preparation |
| 02/01/2007 | CA2554728A1 Production method of nicotine transdermal preparation |
| 01/31/2007 | EP1748048A1 Imidazopyridine compound |
| 01/31/2007 | EP1748046A2 Inhibitors of histone deacetylase |
| 01/31/2007 | EP1748044A1 Thiazole compound and use thereof |
| 01/31/2007 | EP1748043A1 Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them |
| 01/31/2007 | EP1747800A1 Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders |
| 01/31/2007 | EP1747785A1 Cyclodextrins for blood detoxification |
| 01/31/2007 | EP1747784A1 Target gene mimitin of myc |
| 01/31/2007 | EP1747783A1 Oral flora-improving agent, antibacterial agent and growth promoter |
| 01/31/2007 | EP1747782A1 Products for topical application comprising lysophospholipids and fatty acids |
| 01/31/2007 | EP1747781A1 Stable oral pharmaceutical preparation comprising fosfomycin, which is intended for diabetic patients |
| 01/31/2007 | EP1747780A1 Drug for prevention or treatment of diabetes |
| 01/31/2007 | EP1747779A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands |
| 01/31/2007 | EP1747778A1 Antifatigue composition |
| 01/31/2007 | EP1747777A1 Medicinal agent |
| 01/31/2007 | EP1747776A1 Pharmaceutical composition comprising granular pantoprazole |
| 01/31/2007 | EP1747284A2 Diagnosis and therapeutics for cancer |
| 01/31/2007 | EP1747263A2 Improved prebiotic |
| 01/31/2007 | EP1747262A1 Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates |
| 01/31/2007 | EP1747231A1 Aminosulphonyl- or aminosulphonylamino-substituted phenyl esters as estriol and estetrol prodrugs |
| 01/31/2007 | EP1747230A1 Aminosulphonyl-or aminosulphonylamino-substituted phenyl esters as estradiol prodrugs |
| 01/31/2007 | EP1747229A1 Steroid prodrugs with androgenic effect |
| 01/31/2007 | EP1747227A2 Combinatorial selection of phosphorothioate aptamers for tgf-beta |
| 01/31/2007 | EP1747225A1 Crystalline forms of 9-(s)-erythromycylamine |
| 01/31/2007 | EP1747222A1 Pyrimidine derivatives antagonists of vitronectin receptor |
| 01/31/2007 | EP1747221A1 Fused ring nk1 antagonists |
| 01/31/2007 | EP1747220A1 Substituted 1h-pyrrolo 3,2-b, 3,2-c, and 2,3-c¨pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon |
| 01/31/2007 | EP1747219A2 Muscarinic acetylcholine receptor antagonists field of the invention |
| 01/31/2007 | EP1747218A2 Neuropeptide receptor modulators |
| 01/31/2007 | EP1747217A1 Novel substituted thiophenecarboxamides, their production and their use as medicaments |
| 01/31/2007 | EP1747216A1 Substituted pyrrole-2, 5-diones as protein kinase c inhibitors |
| 01/31/2007 | EP1747215A1 Substantially pure 2-{¬2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl|-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor |
| 01/31/2007 | EP1747214A2 Dihydrobenzothiophenes |
| 01/31/2007 | EP1747210A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |
| 01/31/2007 | EP1747208A1 Novel sustained-action bronchodilating agents for use in the treatment of respiratory diseases |
| 01/31/2007 | EP1747206A1 Amino-tetrazoles analogues and methods of use |
| 01/31/2007 | EP1747204A1 Tri-substituted ureas as cytokine inhibitors |
| 01/31/2007 | EP1747202A1 Indazole derivatives and pharmaceutical compositions containing them |
| 01/31/2007 | EP1747201A1 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof |
| 01/31/2007 | EP1747200A1 Alkaloid compounds and their use as anti-malarial drugs |
| 01/31/2007 | EP1747199A1 Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 01/31/2007 | EP1747198A1 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 01/31/2007 | EP1747196A2 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| 01/31/2007 | EP1747195A1 Sulfonamide compounds for the treatment of neurodegenerative disorders |
| 01/31/2007 | EP1747193A1 Benzonitrile derivatives to treat musculoskeletal frailty |
| 01/31/2007 | EP1747192A1 (diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
| 01/31/2007 | EP1747191A1 Substituted cyclohexyl-1,4-diamine derivatives with a chain extension |
| 01/31/2007 | EP1747189A1 Preparation of levalbuterol hydrochloride |
| 01/31/2007 | EP1747182A2 Compounds with activity at estrogen receptor |
| 01/31/2007 | EP1747023A2 Methods and compositions for reducing viral genome amounts in a target cell |
| 01/31/2007 | EP1747021A2 Self-immolative linkers and drug conjugates |
| 01/31/2007 | EP1747017A2 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration |
| 01/31/2007 | EP1747016A2 Use of dipyridamole for treatment of resistance to platelet inhibitors |
| 01/31/2007 | EP1747014A2 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions |
| 01/31/2007 | EP1747008A2 Crude extracts from andrographis paniculata |
| 01/31/2007 | EP1747007A1 Use of chondroitin sulphate e (cs-e ) for the treatment diseases or conditions related to collagen fibril formation. |
| 01/31/2007 | EP1747006A1 Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug |
| 01/31/2007 | EP1747005A2 Geldanamycin compounds and method of use |
| 01/31/2007 | EP1747004A1 Pharmaceutical compositions for metabolic insufficiences |
| 01/31/2007 | EP1747003A1 Phospholipase inhibitors localized in the gastrointestinal lumen |
| 01/31/2007 | EP1747002A2 New apiary veterinary composition |
| 01/31/2007 | EP1747001A2 Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| 01/31/2007 | EP1747000A2 Ethanol extraction of phytosterols from corn fiber |
| 01/31/2007 | EP1746999A1 4-phenylamino-quinazolin-6-yl-amides |
| 01/31/2007 | EP1746998A1 Combination therapy for lower urinary tract symptoms |
| 01/31/2007 | EP1746997A2 3-(4-heteroarylcyclohexylamino) czclopentanecarboxamides as modulators of chemokine receptors |
| 01/31/2007 | EP1746996A1 Compositions for progeny gender control |
| 01/31/2007 | EP1746995A1 Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
| 01/31/2007 | EP1746994A2 Thienopyridinone compounds and methods of treatment |
| 01/31/2007 | EP1746993A1 Controlled release metformin compositions |
| 01/31/2007 | EP1746992A2 Use of n-substituted imino sugars for appetite suppression |
| 01/31/2007 | EP1746991A2 Daao inhibiting benzisoxazoles for treating mental disorders |
| 01/31/2007 | EP1746990A1 Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
| 01/31/2007 | EP1746989A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 01/31/2007 | EP1746988A1 Spiroderivatives for the treatment of hypertension |
| 01/31/2007 | EP1746987A2 Dna pkinase inhibitors for treating cancer and diabetes |
| 01/31/2007 | EP1746986A1 Active substance combination comprising a carbinol combined to at least an nsaid |
| 01/31/2007 | EP1746985A2 Method for augmenting the effects of serotonin reuptake inhibitors |
| 01/31/2007 | EP1746984A2 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
| 01/31/2007 | EP1746983A2 Use of ghrelin antagonists for improving cognition and memory |